Atrial septal defect closure and de novo migraine: Exclusive ticlopidine efficacy.

Abstract

BACKGROUND:

De novo onset or aggravation of migraine has been observed after atrial septal defect closure (ASDC), whereas antiplatelet drugs, such as clopidogrel, used to prevent post-ASDC thromboembolic events, have been associated with migraine amelioration.

CASE:

We report the case of a woman who, after ASDC, experienced de novo severe migraine with aura. Whereas use of acetylsalicylic acid or clopidogrel had no effect, ticlopidine use was associated with migraine amelioration. Migraine relapsed after two ticlopidine dechallenges, and disappeared after drug rechallenges.

CONCLUSION:

A ticlopidine trial could be proposed to patients with migraine which occurs or worsens immediately after ASDC and does not improve with clopidogrel.

• Authors: Silvia Benemei, Eleonora Rossi, Rossella Marcucci, Betti Giusti, Pierangelo Geppetti
• Journal: Cephalalgia : an international journal of headache (Cephalalgia) Vol. 32 Issue 15 Pg. 1144-6 (Nov 2012) ISSN: 1468-2982 [Electronic] England
• PMID: 22992406 (Publication Type: Case Reports, Journal Article)

Chemical References

• Fibrinolytic Agents
• Ticlopidine

Topics

• Adult
• Cardiovascular Surgical Procedures (adverse effects)
• Female
• Fibrinolytic Agents
• Heart Septal Defects, Atrial
• Humans
• Migraine Disorders (drug therapy, etiology, prevention & control)
• Plastic Surgery Procedures (adverse effects)
• Ticlopidine
• Treatment Outcome